Synthesis, molecular modelling and biological evaluation of 4-amino-2(1H)-quinazolinone and 2,4(1H,3H)-quinazolidone derivatives as antitumor agents

Archiv der Pharmazie

Volumn 344, Issue 12, 2011, Pages 810-820

  Richter, Stephanie ^a   Gioffreda, Barbara ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

2,4(1H,3H) Quinazolidone; 4 Amino 2(1H) quinazolinone; Antitumor activity

Indexed keywords

4 AMINO 6 (3,4 DIMETHOXYBENZOYL) 2(1H)QUINAZOLINONE; 4 AMINO 6 (4 CHLOROBENZOYL) 2(1H)QUINAZOLINONE; 4 AMINO 6 (4 CHLOROPHENYLSULFONYL) 2(1H)QUINAZOLINONE; 4 AMINO 6 (4 METHOXYBENZOYL) 2(1H)QUINAZOLINONE; 4 AMINO 6 (4 METHOXYPHENYLSULFONYL) 2(1H)QUINAZOLINONE; 4 AMINO 6 (4 TOLYLSULFONYL) 2(1H)QUINAZOLINONE; 4 AMINO 6 (4 TOLYLTHIO) 2(1H)QUINAZOLINONE; 4 AMINO 6 BENZOYL 2(1H)QUINAZOLINONE; 6 (4 CHLOROPHENYLTHIO) 2,4(1H,3H)QUINAZOLINEDIONE; 6 (4 FLUOROPHENYLTHIO) 2,4(1H,3H)QUINAZOLINEDIONE; 6 (4 TOLYLSULFONYL) 2,4(1H,3H)QUINAZOLINDIONE; 6 (4 TOLYLTHIO) 2,4(1H,3H)QUINAZOLINEDIONE; ANTINEOPLASTIC AGENT; QUINAZOLINONE DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; DRUG CYTOTOXICITY; DRUG SCREENING; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; HUMANS; MODELS, MOLECULAR; QUINAZOLINONES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 82955221888     PISSN: 03656233     EISSN: 15214184     Source Type: Journal    
DOI: 10.1002/ardp.201000312     Document Type: Article

References (25)

1. K. Poreba, A. Opolski, J. Witrzuk, Arch. Pharm. 2001, 334, 4097-4098.
2. A. Gangjee, O. Adaira, S. F. Queener, Bioorg. Med. Chem 2001, 9, 2929-2935.
3. S. Huang, R. Lin, Y. Yu, et al., Bioorg. Med. Chem. Lett. 2007, 17, 1243-1245.
4. A. Maloney, P. Workman, Expert. Opin. Biol. Ther. 2002, 2, 3-24.
5. L. Zhu, X. Xu, J. Chromatogr. A 2003, 991, 151-158.
6. S. Sarno, M. Salvi, R. Battistutta, et al., Biochim. Biophys. Acta, Proteins Proteomics 2005, 1754, 263-270.
7. S. Sarno, M. Ruzzene, P. Frascella, et al., Mol. Cell Biochem. 2005, 274, 69-76.
8. L. Wright, X. Barril, B. Dymock, et al., Chem. Biol. 2004, 11, 775-785.
9. A. Kreusch, S. Han, A. Brinker, et al., Bioorg. Med. Chem. Lett. 2005, 15, 1475-1478.
10. S. S. Kulp, M. J. McGee, J. Org. Chem. 1983, 4097-4098.
11. Y. Suzuki, S. Ota, Y. Fukuta, et al., J. Org. Chem. 2008, 2420-2423.
12. Z. Vejdělek, J. Holubek, M. BuděšínskÃ? , et al., Collect. Czech. Chem. Commun. 1988, 361-372.
13. Y. Liu, Y. Lu, M. Prashad, et al., Adv. Synth. Catal. 2005, 217-219.
14. M. Gopalakrishnan, P. Sureshkumar, V. Kanagarajan, J. Thanusu, Catal. Communi. 2005, 753-756.
15. L. Fullhart Jr, Iowa State College J. Sci. 1947, 27-28.
16. I. Ivanov, Synth. Commun. 2006, 1405-1411.
17. R. B. Davis, D. D. Carlos, G. S. Mattingly, J. Org. Chem. 1965, 2607-2609.
18. W. A. Waters, J. Chem. Soc. 1929, 2106-2111.
19. L. Friedman, H. Shechter, J. Org. Chem. 1961, 2522-2524. [20] A. V. Narender, A. Kamal, P. B. Sattur, Synth. Commun. 1988, 525-530.
20. F. Y. Kwong, S. L. Buchwald, Org. Lett. 2002, 3517-3520
21. E. Sperotto, G. P. M. van Klink, J. G. de Vries, G. van Koten, J. Org. Chem. 2008, 5625-5628
22. W. T. Ashton, J. B. Hynes, J. Med. Chem. 1973, 1233-1237.
23. M. R. Grever, S. A. Schepartz, B. A. Chabner, Semin. Oncol. 1992, 19, 622-638.
24. M. R. Boyd, K. D. Paull, Drug Rev. Res. 1995, 34, 91-109.
25. A. Monks, D. Scudiero, P. Skehan, R. Shoemaker, et al., J. Natl. Cancer Inst. 1991, 83, 757-766.